Bálint Tamaskovics

Adjuvant nivolumab in addition to postoperative radiation therapy in locally advanced head and neck cancer: Results of the phase II NadiHN trial.

Peter Brossart, Henning Schäfer, Susanne Wiegand, Thomas Gauler et autres

6092 Background: The benefit of adding immune checkpoint inhibition to standard postoperative adjuvant radiotherapy in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) with an intermediate risk of recurrence remains unclear. Methods: The phase II, open-label, randomized, multicenter national …

de (code pays fourni par la source)

Newly Identified Transcriptomic Biomarkers and Gene Signature of Pathological Complete Response to Induction Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Jianguo Zhou, Markus Eckstein, Haitao Wang, Tianjun Lan et autres

Neoadjuvant therapies incorporating immune checkpoint inhibitors (ICIs) have shown promise in locally advanced head and neck squamous cell carcinoma (HNSCC). However, biomarkers for pathological complete response (pCR) remain undefined. In the CheckRad-CD8 trial (NCT03426657), we performed RNA sequencing on pre- and post-treatment …

de, cn, mo, fr, ee, at (code pays fourni par la source)

1328MO Hypofractionated radiotherapy of single tumor lesion increases systemic response rate to pembrolizumab in recurrent or metastatic head-and-neck cancer (R/M-HNSCC): Primary endpoint of the randomized Keynote-717 trial

Philipp Schubert, Bálint Tamaskovics, J. Haussmann, W. Budach et autres

de, at, us (code pays fourni par la source)

1445eP PeLeRad: An open-label, randomized multicenter phase II trial of combined pembrolizumab (P) and lenvatinib (L) after definitive chemoradiation of locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in PD-L1 positive patients: Results of an interim analysis

Sören Schnellhardt, Wiebke Pirschel, Maximilian Linxweiler, Patrick Melchior et autres

de, us (code pays fourni par la source)

Promoting interdisciplinarity and the timely integration of palliative care through the development and implementation of a blended learning elective for medical students

Yann-Nicolas Batzler, Manuela Schallenburger, Tabea Sammer, Jan Haussmann et autres

Background: Given demographic changes and a rising prevalence of oncological diseases, understanding the importance of interdisciplinary collaboration and a timely integration of palliative care is crucial. However, both are underrepresented in medical curricula. To address this gap, we introduced a new elective …

de, us (code pays fourni par la source)

Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology

Danny Jazmati, Dennis Sohn, Juliane Hörner‐Rieber, Nan Qin et autres

BACKGROUND: Medulloblastoma is the most common malignant pediatric brain tumor, typically treated with normofractionated craniospinal irradiation (CSI) with an additional boost over about 6 weeks in children older than 3 years. This study investigates the sensitivity of pediatric medulloblastoma cell lines to …

de (code pays fourni par la source)

89 Enhancing Pathological Complete Response in Breast Cancer with Neoadjuvant Chemoradiotherapy: Insights from a Retrospective Study

Jan Haussmann, Danny Jazmati, Stefanie Corradini, Bálint Tamaskovics et autres

129 Low-Dose Radiotherapy for Heel Spurs: A 20-Year Safety and Efficacy Study

Kimia Karimi, Danny Jazmati, Jan Haussmann, Bálint Tamaskovics et autres

First Description of Alpha/Beta Values in Pediatric Medulloblastoma: Implications for Tailored Approaches in Radiation Oncology

Danny Jazmati, Dennis Sohn, Ronja-Linda Preugschas, Nan Qin et autres

de, us (code pays fourni par la source)

Factors influencing pathological complete response and tumor regression in neoadjuvant radiotherapy and chemotherapy for high-risk breast cancer

Jan Haussmann, Wilfried Budach, Carolin Nestle-Krämling, Sylvia Wollandt et autres

BACKGROUND: Pathological complete response (pCR) is a well-established prognostic factor in breast cancer treated with neoadjuvant systemic therapy (naST). The determining factors of pCR are known to be intrinsic subtype, proliferation index, grading, clinical tumor and nodal stage as well as type …

de (code pays fourni par la source)

Corrigendum: Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center

Dániel Deme, Bálint Tamaskovics, Nizar Jammoul, Sándor Kovács et autres

and N0-1 breast cancer: a real-life experience of a North Hungarian regional center

hu, de, us (code pays fourni par la source)

Determinants of pathological complete response and tumor regression in high-risk breast cancer treated with neoadjuvant radiotherapy and chemotherapy.

Jan Haussmann, Wilfried Budach, Carolin Nestle Kraemling, Sylvia Wollandt et autres

e12652 Background: Pathological complete response (pCR) is a recognized prognostic indicator in breast cancer patients undergoing neoadjuvant systemic therapy (naST). Known determinants of pCR include intrinsic subtype, proliferation index, grading, clinical tumor and nodal stage, as well as the type of systemic …

de (code pays fourni par la source)